SYRESpyre Therapeutics, Inc.
$85.70+476% 1Y
$85.70
$15.2952 weeks$108.94
SYRE as reported
Spyre Therapeutics, Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q4 2024 · every figure below is as filed, with no scoring applied
- Net income
- −$179M
Net income · −13% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | n/a | Q4 2024 · 6 quarters behind |
| Net income | −$179M | −13% | Q2 2026 |
| EPS | $1.48 | n/a | Q3 2024 · 7 quarters behind |
| Operating margin | −13707% | n/a | Q2 2023 · 12 quarters behind |
| Net margin | −15635% | n/a | Q2 2023 · 12 quarters behind |
| ROE | −24% | n/a | Q2 2026 |
| ROA | −22% | n/a | Q2 2026 |
| Free cash flow | −$80M | n/a | Q4 2022 · 14 quarters behind |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Spyre Therapeutics, Inc. (SYRE) · Revenue and profitRevenue and profitSpyre Therapeutics, Inc. (SYRE)
RevenueNet incomeTrailing twelve months
Powered byryufin.com
On our screens:Most shorted stocks